Jiang, X; Hu, C; Ferchen, K; Nie, J; Cui, X; Chen, C; Cheng, L; Zuo, Z; Seibel, W; He, C; et al.
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.
Nature Communications.
2017;
8.
Eriksson, M; Pena-Martinez, P; Ramakrishnan, R; Chapellier, M; Hogberg, C; Glowacki, G; Orsmark-Pietras, C; Velasco-Hernandez, T; Lazarevic, VL; Juliusson, G; et al.
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.
Blood Advances.
2017;
1:2046-2057.
Mizukawa, B; O'Brien, E; Moreira, DC; Wunderlich, M; Hochstetler, CL; Duan, X; Liu, W; Orr, E; Grimes, HL; Mulloy, JC; et al.
The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
Blood.
2017;
130:1336-1346.
Lin, S; Ptasinska, A; Chen, X; Shrestha, M; Assi, SA; Chin, PS; Imperato, MR; Aronow, BJ; Zhang, J; Weirauch, MT; et al.
A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
Blood.
2017;
130:1213-1222.
Lin, S; Luo, RT; Shrestha, M; Thirman, MJ; Mulloy, JC.
The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.
Blood.
2017;
130:903-907.
Bertaux-Skeirik, N; Wunderlich, M; Teal, E; Chakrabarti, J; Biesiada, J; Mahe, M; Sundaram, N; Gabre, J; Hawkins, J; Jian, G; et al.
CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium.
The Journal of pathology and bacteriology.
2017;
242:463-475.
Kobayashi, M; Chen, S; Bai, Y; Yao, C; Gao, R; Sun, X; Mu, C; Twiggs, TA; Yu, Z; Boswell, HS; et al.
Phosphatase PRL2 promotes AML1-ETO-induced acute myeloid leukemia.
Leukemia.
2017;
31:1453-1457.
Goyama, S; Shrestha, M; Schibler, J; Rosenfeldt, L; Miller, W; O'Brien, E; Mizukawa, B; Kitamura, T; Palumbo, JS; Mulloy, JC.
Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.
Oncogene: Including Oncogene Reviews.
2017;
36:2589-2598.
Chen, X; Clark, J; Wunderlich, M; Fan, C; Davis, A; Chen, S; Guan, J; Mulloy, JC; Kumar, A; Zheng, Y.
Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.
Autophagy.
2017;
13:955-966.
Kesarwani, M; Kincaid, Z; Gomaa, A; Huber, E; Rohrabaugh, S; Siddiqui, Z; Bouso, MF; Latif, T; Xu, M; Komurov, K; et al.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Nature Medicine.
2017;
23:472-482.
Lin, S; Mulloy, JC; Goyama, S.
RUNX1-ETO Leukemia.
Editor, Groner Y; Ito Y; Liu P; Neil JC; Speck NA; VanWijnen A.
Advances in Experimental Medicine and Biology.
2017;
962:151-173.